Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
World game at war: why some European nations have threatened a World Cup boycott 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
HALIFAX, Nova Scotia, April 23, 2018 -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada.
Details of the presentation are as follows:
- Date: Thursday, May 3, 2018
- Time: 2:30 pm ET
- Location: Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada
About the Conference
Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest development in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.
About Immunovaccine
Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology provides controlled and prolonged exposure to a broad range of immunogenic stimuli. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of its platform, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects in malaria and Zika virus. Connect at www.imvaccine.com.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: [email protected]
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: [email protected]
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: [email protected]
